Resultado real com GLP-1: o que a ciência diz sobre perda de peso em 6 meses

Six months into treatment, patients on GLP-1 receptor agonists show an average weight reduction of 10 to 15 percent of initial body weight, according to multiple randomized controlled trials. That number is not marketing. It is not a before-and-after photo with ideal lighting. It is what the data consistently shows across populations, ages and baseline weights.

The most cited evidence comes from the SUSTAIN and STEP programs, which evaluated semaglutide and tirzepatide across thousands of participants over at least a year. In the STEP 1 trial, participants using semaglutide 2.4 mg lost approximately 14.8 percent of body weight after 68 weeks. The 6-month mark falls roughly in the middle of that timeline, and the trajectory at that point is typically around 8 to 12 percent depending on individual adherence, dose reached and metabolic baseline.

What that actually means in practice differs from the headlines. A person who starts at 95 kilograms does not arrive at 83 after six months like the math suggests on paper. Weight loss with GLP-1 follows a curve. The initial drop in the first one to two months tends to be faster, driven largely by water weight and reduced caloric intake from appetite suppression. After that, the rate slows. The body defends its current weight even as the medication continues working.

The reason many people stall around month four or five is not that the drug stopped working. It is that the body reached a new equilibrium. Leptin levels adjust, ghrelin production settles into the new baseline, and energy expenditure adapts to the reduced intake. The medication still suppresses appetite. The calories consumed still drop. But the pace of loss flattens out because the system is stabilizing.

Tirzepatide, marketed as Mounjaro, shows a steeper curve in head-to-head comparisons. In the SURPASS-2 trial, tirzepatide 10 mg produced a 12.4 percent weight reduction at 40 weeks, already exceeding what semaglutide showed at a similar timepoint. At six months on tirzepatide, participants typically show 10 to 13 percent reduction. The magnitude depends heavily on which dose they reached and how well they tolerate it.

Individual factors determine how much you lose in six months. Starting weight is the most obvious. Someone with 40 kilograms to lose will typically see a higher absolute number than someone with 15, even if the percentage is similar. Age plays a role because metabolic rate tends to decline over decades, making sustained loss harder as time passes. Baseline metabolic conditions like hypothyroidism, polycystic ovary syndrome or long-term caloric restriction damage all influence how the body responds.

Adherence matters more than most people expect. GLP-1 medications are not magic. They require consistent dosing, progressive dose escalation as tolerated and attention to nutrition. Skipping doses, plateauing at the lowest dose out of fear of side effects, or not adjusting eating patterns to match the reduced appetite will produce results far below what the trials show. The gap between clinical trial conditions and real-world use explains much of the difference between published averages and individual experiences.

Side effects also influence outcome. About 20 to 30 percent of participants in major trials discontinued treatment due to adverse events, primarily gastrointestinal. Nausea, diarrhea, constipation and heartburn are common early in treatment. Most people push through with dose adjustments and supportive care. Those who stop, obviously, stop losing weight.

One thing the data consistently shows is that the people who do best are those who combine the medication with meaningful changes in eating behavior and some form of physical activity. Not extreme restriction. Not marathon training. But protein-forward nutrition that preserves muscle mass during the deficit, and resistance training that signals the body to hold onto lean tissue rather than burning it for fuel.

Keeping a record of what happens as you go makes a real difference. Not just weight on the scale, but how you feel after meals, whether nausea appears after certain foods, how your energy levels shift through the day. The OzemPro app allows you to track all of that in one place. Symptoms, doses, weight and notes all stay organized so you can see patterns over time instead of relying on memory. Comece por aqui and build the habit before the data gets complicated.

The body composition question is important to address. Weight loss on GLP-1 does not discriminate between fat and muscle the way many diets do. The appetite reduction is substantial enough that caloric deficit can become quite significant, and without intentional protein intake and resistance work, muscle loss can account for 20 to 30 percent of total weight lost. That is not trivial. Muscle loss affects metabolic rate, functional strength and the visual result of the fat loss. It also increases the likelihood of rebound weight gain once the medication is reduced or stopped.

A practical protein target during active GLP-1 therapy is 1.2 to 1.6 grams per kilogram of target body weight per day, distributed across three or four meals. That is higher than general recommendations because the anabolic signal from protein needs to be strong enough to overcome the catabolic pressure of a sustained caloric deficit. Whey protein, skyr, Greek yogurt, fish and legumes cover most of the bases.

On the physical activity side, the goal should be resistance training at least twice per week targeting major muscle groups, plus walking or another low-intensity aerobic activity for 150 minutes or more weekly. This is not about burning calories in the session. It is about convincing the body that muscle is necessary and worth preserving while fat is being mobilized.

The question of what happens after six months comes up frequently. The trials continue beyond that point, and the pattern is clear: people who stay on the medication continue losing, more slowly, for as long as they remain on it. Those who discontinue tend to regain about two-thirds of the lost weight within a year, according to the STEP 1 extension data. That is not a flaw in the medication. It reflects the biology of appetite regulation and energy homeostasis. The underlying drivers of weight gain do not disappear just because the medication suppressed them temporarily.

For someone in the early months of GLP-1 therapy, the six-month mark is a useful checkpoint. Where do you stand relative to the trial averages. Are you on a dose that is clinically meaningful. Have you tracked your symptoms and weight in a way that allows your prescriber to make real adjustments. Have you started building the habits that will matter when the medication dose stabilizes or, someday, when you consider tapering.

Most people who have a good experience at six months share a few characteristics. They stayed on the medication even when the initial weeks were uncomfortable. They titrated up to a dose that actually moved the needle on their appetite. They paid attention to protein intake. They found a form of movement they could sustain without needing to feel motivated every time. And they tracked things so they had actual data to work from instead of impressions.

The OzemPro app is built exactly for this. Track your weight, your doses, how you slept, what you ate, how you felt. All of it stays in one place. No separate spreadsheet. No trying to remember what your weight was six weeks ago. When you go to your appointment, you have a full picture ready. Acesse aqui pra conhecer and bring actual information to every decision about your treatment.

The science is clear that GLP-1 based weight loss is real, measurable and sustained when the medication is used appropriately. What varies is how well individuals use the support system around them, track their progress, and build habits that last beyond the medication itself.